Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 130,000 shares of common stock with an exercise price of $5.33 per share.
The stock options, approved under the Company's 2022 Inducement Plan, will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), una società biofarmaceutica in fase clinica specializzata in terapie per il cancro al seno, ha assegnato opzioni su azioni a quattro nuovi dipendenti. Le assegnazioni ammontano a un totale di 130.000 azioni ordinarie con un prezzo di esercizio di 5,33 $ per azione.
Le opzioni azionarie, approvate nell'ambito del Piano di Incentivazione 2022 della Società, matureranno in un periodo di quattro anni, con il 25% che matura dopo il primo anno e il resto che matura mensilmente nei successivi tre anni. Le opzioni hanno una durata di 10 anni e sono state concesse in conformità con la Regola 5635(c)(4) del Nasdaq.
Olema Oncology (Nasdaq: OLMA), una compañía biofarmacéutica en etapa clínica enfocada en terapias para el cáncer de mama, ha otorgado opciones sobre acciones a cuatro nuevos empleados. Las concesiones suman un total de 130,000 acciones comunes con un precio de ejercicio de $5.33 por acción.
Las opciones sobre acciones, aprobadas bajo el Plan de Incentivos 2022 de la Compañía, se consolidarán durante cuatro años, con un 25% consolidado tras el primer año y el resto consolidándose mensualmente durante los siguientes tres años. Las opciones tienen un plazo de 10 años y fueron otorgadas conforme a la Regla 5635(c)(4) de Nasdaq.
Olema Oncology (나스닥: OLMA)는 유방암 치료제에 집중하는 임상 단계 바이오제약 회사로, 4명의 신입 직원에게 주식 매수선택권을 부여했습니다. 부여된 주식은 총 130,000주의 보통주이며, 행사가격은 주당 5.33달러입니다.
이 주식 매수선택권은 회사의 2022년 인센티브 플랜에 따라 승인되었으며, 4년에 걸쳐 권리가 취득됩니다. 1년 후 25%가 취득되고 나머지는 3년 동안 매월 취득됩니다. 옵션의 유효기간은 10년이며, 나스닥 상장 규정 5635(c)(4)에 따라 부여되었습니다.
Olema Oncology (Nasdaq : OLMA), une société biopharmaceutique en phase clinique spécialisée dans les thérapies contre le cancer du sein, a accordé des options d'achat d'actions à quatre nouveaux employés. Les attributions totalisent 130 000 actions ordinaires avec un prix d'exercice de 5,33 $ par action.
Les options d'achat d'actions, approuvées dans le cadre du Plan d'Incitation 2022 de la Société, seront acquises sur une période de quatre ans, avec 25 % acquis après la première année et le reste acquis mensuellement sur les trois années suivantes. Les options ont une durée de 10 ans et ont été accordées conformément à la règle 5635(c)(4) du Nasdaq.
Olema Oncology (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Therapien gegen Brustkrebs spezialisiert hat, hat Aktienoptionen an vier neue Mitarbeiter gewährt. Die Zuteilungen umfassen insgesamt 130.000 Stammaktien mit einem Ausübungspreis von 5,33 $ pro Aktie.
Die Aktienoptionen, die im Rahmen des Inducement Plans 2022 des Unternehmens genehmigt wurden, werden über vier Jahre vesten, wobei 25 % nach dem ersten Jahr und der Rest monatlich über die folgenden drei Jahre vesten. Die Optionen haben eine 10-jährige Laufzeit und wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- None.
- None.
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 130,000 shares of the Company's common stock, effective as of August 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What stock options did Olema Oncology (OLMA) grant to new employees in August 2025?
What is the vesting schedule for Olema Oncology's (OLMA) August 2025 employee stock options?
What is the exercise price for Olema Oncology's (OLMA) August 2025 inducement grants?
Under which plan were Olema Oncology's (OLMA) August 2025 stock options granted?
